A carregar...
Assessment of Off-label Prescribing Compared With FDA-Approved Treatment With Combined Dextromethorphan and Quinidine in 2 Commercial Insurance Databases
IMPORTANCE: In 2010, the US Food and Drug Administration approved a combination of dextromethorphan hydrobromide and quinidine sulfate with an Orphan Drug Act designation for the treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This me...
Na minha lista:
| Publicado no: | JAMA Intern Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142962/ https://ncbi.nlm.nih.gov/pubmed/30039158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2018.3016 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|